Omeprazol Mylan (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Mylan, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid secretion and is used to treat conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease, Zollinger‑Ellison syndrome and to protect against NSAID‑induced ulcers in adults.

GNH USA supplies Omeprazol Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole acts on the gastric proton pump to lower acid production, making it useful for several acid‑related disorders. - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal irritation. - Peptic ulcer disease: accelerates ulcer healing and reduces recurrence. - NSAID‑induced ulcer prophylaxis: protects the stomach lining in patients taking non‑steroidal anti‑inflammatory drugs. - Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion.

Adverse reactions may occur with any medication and should be monitored.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limited. - Nausea or vomiting: transient gastrointestinal upset. - Abdominal pain: mild discomfort. - Flatulence: increased gas production. - Constipation: occasional bowel changes.

Serious or Rare Side Effects: - Acute interstitial nephritis: renal inflammation requiring medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Clostridioides difficile infection: severe colitis risk. - Bone fracture risk: long‑term use may affect bone density. - Low magnesium levels: may cause muscle cramps or cardiac arrhythmia. - Vitamin B12 deficiency: possible with prolonged therapy.

Patients should be aware of specific safety considerations before using Omeprazole. - Assess renal and hepatic function: dose adjustment may be needed in impairment. - Review concomitant medications: potential for reduced efficacy of drugs requiring acidic pH. - Monitor for infection signs: prolonged acid suppression can increase gastrointestinal infection risk. - Evaluate bone health: long‑term therapy may warrant calcium and vitamin D supplementation. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can alter the pharmacokinetics of several drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect; consider alternative therapy. - Atazanavir or other protease inhibitors: markedly decreased absorption; avoid co‑administration. - Warfarin: enhanced anticoagulant effect; monitor INR closely.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum levels; check concentrations. - Methotrexate (high dose): reduced clearance; monitor for toxicity. - Phenytoin: decreased plasma concentration; adjust dose if needed.